Gut/brain Axis and its Role in Parkinson’s Disease Progression

Supplemental Files
Date
2019-01-01
Authors
Myers, Kendra
Major Professor
Jonathan Mochel
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Research Projects
Organizational Units
Biomedical Sciences
Organizational Unit
Journal Issue
Series
Department
Biomedical Sciences
Abstract

The gut/brain access has a significant role in disease progression in Parkinson’s disease. There are several hypotheses for what is causing the progression itself; one of which is that the microbiome in the GI is creating SCFAs that are able to increase inflammation, a-synuclein originates in the GI and is able to travel to the brain causing a-synuclein aggregation and inflammation, and that the overall inflammation in the brain is causing activation of microglia causing increased a-synuclein aggregation. It is unknown which of these is causing the disease, but they all have been shown to have a role. It is known that a-synuclein aggregates cause motor symptoms and there is evidence to show that it originates from the dysbiosis of the GI microbiota. a-synuclein in the CNS activates microglia cells, increasing proinflammatory cytokines TNF-a and IL-6. The short chain fatty acids produced by fermentation byproducts of the gut microbiome play a role on the enteric nervous system and can be a major player of the nonmotor symptoms displayed by Parkinson’s disease patients and increasing inflammation. Lastly, the microbiome of Parkinson’s disease patients is altered from a normal gut microbiome to a disease-causing form. All of these factors play a role in Parkinson’s disease progression but the main treatment (L-DOPA) does not directly impact any of these factors.

Comments
Description
Keywords
Citation
DOI
Source